Switch to faricimab in various retinal diseases: real-world data.

IF 1.4 4区医学 Q3 OPHTHALMOLOGY

International Ophthalmology Pub Date : 2026-05-02 DOI:10.1007/s10792-026-04092-w

Eitan Kaplan, Ori Segal, Elad Moisseiev, GIlad Allon

{"title":"Switch to faricimab in various retinal diseases: real-world data.","authors":"Eitan Kaplan, Ori Segal, Elad Moisseiev, GIlad Allon","doi":"10.1007/s10792-026-04092-w","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy of faricimab in various retinal conditions in previously treated patients.Methods: This study included patients who received at least three faricimab injections at a large medical center between April 2023 and October 2024, all of whom were not naive to treatment.Results: A total of 242 eyes from 219 patients were included in the analysis. The diagnoses were: 139 eyes with neovascular age-related macular degeneration (NVAMD), 63 eyes with diabetic macular edema (DME), 24 eyes with polypoidal choroidal vasculopathy (PCV), 5 eyes with choroidal neovascularization (CNV) secondary to central serous retinopathy (CSR), 5 eyes with branch retinal vein occlusion (BRVO) accompanied by cystoid macular edema (CME), 3 eyes with central retinal vein occlusion (CRVO) with CME, and 3 eyes with myopic CNV. Patients had previously received intravitreal injections of medications including bevacizumab, ranibizumab, aflibercept 2 mg, brolucizumab, triamcinolone, and Ozurdex. Following treatment with faricimab, the proportion of eyes with no intraretinal or subretinal fluid increased across all retinal diseases. Additionally, the average central subfield thickness decreased, the interval between injections was extended, and average visual acuity improved in every retinal condition. The average height of the pigment epithelium detachment (PED) decreased in cases of NVAMD and PCV.Conclusions: Faricimab appears to be effective after the failure of other treatment options.","PeriodicalId":14473,"journal":{"name":"International Ophthalmology","volume":"46 1","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10792-026-04092-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy of faricimab in various retinal conditions in previously treated patients.

Methods: This study included patients who received at least three faricimab injections at a large medical center between April 2023 and October 2024, all of whom were not naive to treatment.

Results: A total of 242 eyes from 219 patients were included in the analysis. The diagnoses were: 139 eyes with neovascular age-related macular degeneration (NVAMD), 63 eyes with diabetic macular edema (DME), 24 eyes with polypoidal choroidal vasculopathy (PCV), 5 eyes with choroidal neovascularization (CNV) secondary to central serous retinopathy (CSR), 5 eyes with branch retinal vein occlusion (BRVO) accompanied by cystoid macular edema (CME), 3 eyes with central retinal vein occlusion (CRVO) with CME, and 3 eyes with myopic CNV. Patients had previously received intravitreal injections of medications including bevacizumab, ranibizumab, aflibercept 2 mg, brolucizumab, triamcinolone, and Ozurdex. Following treatment with faricimab, the proportion of eyes with no intraretinal or subretinal fluid increased across all retinal diseases. Additionally, the average central subfield thickness decreased, the interval between injections was extended, and average visual acuity improved in every retinal condition. The average height of the pigment epithelium detachment (PED) decreased in cases of NVAMD and PCV.

Conclusions: Faricimab appears to be effective after the failure of other treatment options.

查看原文本刊更多论文

改用法利昔单抗治疗各种视网膜疾病：真实世界的数据。

目的：评价法利西单抗治疗既往视网膜病变的疗效。方法：本研究纳入了2023年4月至2024年10月期间在一家大型医疗中心接受至少三次法利西单抗注射的患者，所有患者都不是初次接受治疗。结果：219例患者共242只眼纳入分析。诊断为：新生血管性年龄相关性黄斑变性（NVAMD） 139眼，糖尿病性黄斑水肿（DME） 63眼，息肉样脉络膜血管病变（PCV） 24眼，继发于中枢性浆液性视网膜病变（CSR）的脉络膜新生血管病变（CNV） 5眼，视网膜分支静脉阻塞（BRVO）伴囊样黄斑水肿（CME） 5眼，视网膜中央静脉阻塞（CRVO）伴CME 3眼，近视CNV 3眼。患者以前接受过玻璃体内注射药物，包括贝伐单抗、雷尼单抗、阿非利塞普2mg、brolucizumab、曲安奈德和Ozurdex。在法利西单抗治疗后，在所有视网膜疾病中没有视网膜内或视网膜下积液的眼睛比例增加。此外，平均中心亚场厚度下降，注射间隔延长，平均视力改善，在每一个视网膜条件。NVAMD和PCV患者色素上皮脱离（PED）的平均高度降低。结论：在其他治疗方案失败后，Faricimab似乎是有效的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Ophthalmology OPHTHALMOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

451

期刊介绍： International Ophthalmology provides the clinician with articles on all the relevant subspecialties of ophthalmology, with a broad international scope. The emphasis is on presentation of the latest clinical research in the field. In addition, the journal includes regular sections devoted to new developments in technologies, products, and techniques.